Does J3121 require prior authorization?

No, J3121 does not require prior authorization (high confidence). Code is covered without prior authorization.

What is the Medicare reimbursement rate for J3121?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

This billing and coding guidance must be used in conjunction with the associated Local Coverage Determination (LCD).
The patient's medical record must document medical necessity, including relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.
For services requiring a referring/ordering physician, the referring/ordering physician's name and NPI must be reported on the claim.
A claim submitted without a valid ICD‑10‑CM diagnosis code that best describes the condition will be returned as an incomplete claim under §1833(e) of the Social Security Act.

Medicare may cover injectable testosterone pellets (Testopel) for males when used for an FDA‑approved indication and when the service meets Medicare coverage requirements in CMS Medicare Benefit Policy Manual, Chapter 15, §50.4.3.
Injectable testosterone pellet therapy may be used when alternative accepted routes (transdermal, oral, nasal, intramuscular) are clinically inappropriate or insufficient and medical necessity is documented.
Testosterone replacement may be considered for men with clinically significant symptoms of androgen deficiency AND two separate morning serum total testosterone levels low on two different days and a single LH or FSH measurement documented in the chart.
Primary hypogonadism (low testosterone with elevated LH and/or FSH) is an indication for consideration of testosterone replacement therapy when documented with symptoms and lab results.
If two low morning testosterone determinations are present together with low LH/FSH, testosterone therapy may be considered only after evaluation and exclusion of pituitary disease (including serum prolactin) or chronic disease as the cause of hypogonadism.
Only patients with low testosterone associated significant symptoms should be considered for treatment.

FIRST_COAST-L40314 — Trigger Point Injections

J9 MAC Part B

NORIDIAN-L36538 — Treatment of Males with Low Testosterone

JF Part B

PALMETTO-L39086 — Treatment of Males with Low Testosterone

JJ Part B

NOVITAS-L40310 — Trigger Point Injections

JL MAC Part B

Ask Verity about documentation requirements, denial risks, or coverage in your state.